Stockscreener 앱 받기
2.57
1.91%
-0.05
시간 외 거래:
2.56
-0.010
-0.39%
전일 마감가:
$2.62
열려 있는:
$2.53
하루 거래량:
14,780
Relative Volume:
0.03
시가총액:
$11.39M
수익:
$20,000
순이익/손실:
$-11.06M
주가수익비율:
-0.9034
EPS:
-2.8449
순현금흐름:
$-10.53M
1주 성능:
-2.28%
1개월 성능:
+2.80%
6개월 성능:
+25.37%
1년 성능:
-12.59%
1일 변동 폭
$2.49
$2.60
1주일 범위
$2.45
$2.69
52주 변동 폭
$1.7645
$3.29
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
858-224-9600
주소
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.57 | 10.90M | 20,000 | -11.06M | -10.53M | -2.8449 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
KPRXKiora Pharmaceuticals Inc. stock news, filings & ratings - Quantisnow
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickStock Buy Zone - newsline.com
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Nantahala holds 148,736 shares in Kiora Pharmaceuticals (KPRX) as 3.388% stake - Stock Titan
TradingKey - TradingKey
Number of shareholders of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
EDGAR Filing Documents for 0001372514-23-000110 - SEC.gov
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora (NASDAQ: KPRX) details Q1 2026 results and cash runway to 2028 - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) reports Q1 loss but sees cash runway into late 2028 - Stock Titan
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Is Kiora Pharmaceuticals (KPRX) stock hiding in plain sight? (Risk Aversion) 2026-05-07Take Profit Levels - newser.com
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
KPRX Kiora Pharmaceuticals reports far wider Q4 2025 loss than estimates, shares hold flat in today’s trading. - newser.com
Kiora Pharmaceuticals (NASDAQ: KPRX) details 2026 director, pay and equity plan votes - Stock Titan
KPHMW SEC FilingsKiora Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) Industry Outlook | Q4 2025: Earnings UnderperformRevision Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
KPRX Kiora Pharmaceuticals posts far wider Q4 2025 loss than estimates, shares dip nearly 2 percent today.Cycle Outlook - Cổng thông tin điện tử tỉnh Tây Ninh
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - TMX Newsfile
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Breakouts Watch: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Trend Recap: Will Kiora Pharmaceuticals Inc outperform its industry peers2026 Sentiment & Daily Profit Maximizing Tips - baoquankhu1.vn
What accelerates growth of Kiora Pharmaceuticals (KPRX) Stock | Price at $2.39, Down 3.24%AAII Bearish - newsline.com
Profit Review: Is Kiora Pharmaceuticals Inc a cyclical or defensive stock2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
KPRX Technical Analysis & ETF Price Forecast - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):